Legend Biotech Corp
NASDAQ:LEGN
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
23.36
44.32
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Legend Biotech Corp
Accounts Receivables
Legend Biotech Corp
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Legend Biotech Corp
NASDAQ:LEGN
|
Accounts Receivables
$6.3m
|
CAGR 3-Years
-50%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Accounts Receivables
$12.8B
|
CAGR 3-Years
6%
|
CAGR 5-Years
9%
|
CAGR 10-Years
11%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Accounts Receivables
$5.1B
|
CAGR 3-Years
5%
|
CAGR 5-Years
5%
|
CAGR 10-Years
-2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Accounts Receivables
$8.5B
|
CAGR 3-Years
17%
|
CAGR 5-Years
16%
|
CAGR 10-Years
11%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Accounts Receivables
$1.9B
|
CAGR 3-Years
12%
|
CAGR 5-Years
20%
|
CAGR 10-Years
28%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Accounts Receivables
$5.7B
|
CAGR 3-Years
1%
|
CAGR 5-Years
7%
|
CAGR 10-Years
15%
|
|
Legend Biotech Corp
Glance View
Legend Biotech Corp., an emerging leader in the biotechnology arena, has carved out a niche at the forefront of cellular therapeutics, focusing on transforming cancer treatment paradigms. Born out of the ambition to explore innovative medical frontiers, Legend Biotech embarked on a mission to develop Car-T cell therapies—a personalized form of immunotherapy that employs genetically altered T-cells to target and eradicate cancer cells. With its signature product, Carvykti (ciltacabtagene autoleucel), Legend Biotech has been making waves in the oncology sector. By redirecting the body's own immune system against multiple myeloma, a rare and challenging form of cancer, the company has demonstrated the potential to achieve deep and lasting remissions, bringing hope where conventional treatments may fall short. The financial model of Legend Biotech is driven by strategic partnerships, extensive research and development initiatives, and successful navigation through complex regulatory landscapes. Partnering with Johnson & Johnson's subsidiary Janssen Biotech, the collaboration capitalizes on their combined expertise to advance Car-T technology. Revenues primarily flow from milestone payments upon achieving specific developmental goals, along with royalties derived from global sales of their breakthrough treatments. By investing heavily in R&D and ensuring a robust pipeline of therapeutic candidates, Legend Biotech positions itself for sustainable growth, striving to extend their innovative treatments to a broader range of cancers and, eventually, achieve profitability through expanded indications and market reach.
See Also
What is Legend Biotech Corp's Accounts Receivables?
Accounts Receivables
6.3m
USD
Based on the financial report for Dec 31, 2024, Legend Biotech Corp's Accounts Receivables amounts to 6.3m USD.
What is Legend Biotech Corp's Accounts Receivables growth rate?
Accounts Receivables CAGR 5Y
-27%
Over the last year, the Accounts Receivables growth was -94%. The average annual Accounts Receivables growth rates for Legend Biotech Corp have been -50% over the past three years , -27% over the past five years .